Debate 3: Oligometastatic Hormone Sensitive Prostate Cancer Management: Systemic Therapy Approach

GvA: Consultancy: Roche, BMS, Astellas, Bayer, Janssen, MSD, Ipsen, Pfizer, Astra Zeneca, Merck, Lilly, Novartis; Research Funding within clinical trials: Roche, BMS, MSD/ Merck, Astra Zeneca, Pfizer, Exelixis, Ipsen, Lilly, AvenCell, Bayer, Astellas, Amgen; Honoraria: Roche, BMS, Astellas, Sanofi, Ipsen, EISAI, MSD, Astra Zeneca, Janssen, Merck; Patents and Royalties: not applicable; Membership on an entity’s Board of Directors or advisory committees: Roche, BMS, Astellas, Sanofi, Janssen,

Comments (0)

No login
gif